Evoke Pharma Free Cash Flow 2012-2024 | EVOK
Evoke Pharma free cash flow from 2012 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Evoke Pharma Annual Free Cash Flow |
| 2023 |
-4.99 |
| 2022 |
-6.60 |
| 2021 |
-12.35 |
| 2020 |
-6.63 |
| 2019 |
-5.76 |
| 2018 |
-6.98 |
| 2017 |
-8.72 |
| 2016 |
-8.71 |
| 2015 |
-10.50 |
| 2014 |
-11.50 |
| 2013 |
-3.04 |
| 2012 |
-1.75 |
| 2011 |
-2.89 |
| Evoke Pharma Quarterly Free Cash Flow |
| 2024-09-30 |
-4.22 |
| 2024-06-30 |
-3.40 |
| 2024-03-31 |
-2.58 |
| 2023-12-31 |
-4.99 |
| 2023-09-30 |
-3.88 |
| 2023-06-30 |
-2.84 |
| 2023-03-31 |
-1.63 |
| 2022-12-31 |
-6.60 |
| 2022-09-30 |
-4.09 |
| 2022-06-30 |
-2.99 |
| 2022-03-31 |
-1.62 |
| 2021-12-31 |
-12.35 |
| 2021-09-30 |
-10.36 |
| 2021-06-30 |
-4.46 |
| 2021-03-31 |
-2.95 |
| 2020-12-31 |
-6.63 |
| 2020-09-30 |
-4.92 |
| 2020-06-30 |
-3.11 |
| 2020-03-31 |
-1.55 |
| 2019-12-31 |
-5.76 |
| 2019-09-30 |
-4.61 |
| 2019-06-30 |
-3.56 |
| 2019-03-31 |
-1.93 |
| 2018-12-31 |
-6.98 |
| 2018-09-30 |
-5.73 |
| 2018-06-30 |
-4.58 |
| 2018-03-31 |
-2.82 |
| 2017-12-31 |
-8.72 |
| 2017-09-30 |
-5.98 |
| 2017-06-30 |
-3.78 |
| 2017-03-31 |
-1.69 |
| 2016-12-31 |
-8.71 |
| 2016-09-30 |
-7.34 |
| 2016-06-30 |
-4.92 |
| 2016-03-31 |
-2.69 |
| 2015-12-31 |
-10.50 |
| 2015-09-30 |
-8.04 |
| 2015-06-30 |
-5.54 |
| 2015-03-31 |
-3.00 |
| 2014-12-31 |
-11.50 |
| 2014-09-30 |
-8.98 |
| 2014-06-30 |
-5.07 |
| 2014-03-31 |
-2.00 |
| 2013-12-31 |
-3.04 |
| 2013-09-30 |
-1.15 |
| 2013-06-30 |
-0.88 |
| 2013-03-31 |
-0.45 |
| 2012-12-31 |
|
| 2012-09-30 |
-1.10 |
| 2012-06-30 |
-0.80 |
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.007B |
$0.005B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
